[Establishment and characterization of A549 tumor monoclonal cell line with UCHL1 gene deletion]

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
• Ubiquitin C-terminal hydrolase-L1 (UCHL1) is implicated in various cancers, but its role in NSCLC progression remains unclear.
• Understanding UCHL1's function is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the functional role of UCHL1 in the A549 NSCLC cell line.
• To determine the impact of UCHL1 gene knockout on A549 cell proliferation, cell cycle, cisplatin sensitivity, and migration.
• To explore the association between UCHL1 expression and the Erk1/2 signaling pathway.

Main Methods:

• CRISPR-Cas9 gene editing was employed to create a UCHL1 knockout A549 cell line.
• Quantitative reverse transcription PCR (RT-PCR) and Western blotting were used to confirm UCHL1 gene and protein level changes.
• Cell proliferation (CCK-8 assay), cell cycle (flow cytometry), cisplatin sensitivity (CCK-8 assay), cell migration (scratch assay, Transwell assay), and p-Erk expression (Western blot) were analyzed.

Main Results:

• Successful construction of UCHL1 knockout A549 cells via CRISPR-Cas9.
• No significant alterations in cell proliferation or cell cycle distribution were observed post-UCHL1 knockout.
• UCHL1 gene knockout led to decreased sensitivity to cisplatin and reduced cell migration.
• A notable increase in p-Erk expression levels was detected in UCHL1 knockout cells.

Conclusions:

• Loss of UCHL1 function in A549 cells impairs cisplatin sensitivity and migratory potential.
• The observed effects of UCHL1 knockout may be mediated by the activation of the Erk1/2 signaling pathway.
• These findings highlight UCHL1 as a potential therapeutic target in non-small cell lung cancer.